Journal of Experimental & Clinical Cancer Research 2023

6 papers
In 2023, the Journal of Experimental & Clinical Cancer Research emphasized the molecular mechanisms of the metastatic cascade and the reprogramming of the tumor microenvironment. Research explored how tumor cell-induced platelet aggregation facilitates melanoma metastasis via macrophage recruitment and how metabolic shifts, such as ACLY activation, drive hepatocellular carcinoma progression under endoplasmic reticulum stress. These studies reflect a broader focus on metabolic reprogramming and the identification of functional gatekeepers in cancer survival and therapy resistance. The year’s edition also highlighted epitranscriptomic regulations and post-translational modifications. Notable work investigated METTL3-mediated m6A methylation in breast cancer and the role of the MiR-29b/Sp1/FUT4 axis in leukemia stem cell malignancy. Investigations into molecular leads, including oridonin and toosendanin, aimed to address therapeutic evasion by targeting specific protein translations and transactivations. Prolific authors such as Gan-Lin Zhang and Guowang Yang contributed to these efforts, focusing on enhancing translational robustness in preclinical models to better understand the resilient seeds of cancer relapse.

Top Research Directions

The 19 research directions with Journal of Experimental & Clinical Cancer Research 2023 papers, ranked by paper count, next to 2022. Share is the fraction of the edition’s papers in the direction.

#Direction20232022Share 2023Share 20222022 rank
1Bidirectional Functional Validation of Gene Expression in Disease Models1016.7%0.0%—
2Codon Biased Translation and Ribosome Specialization1016.7%0.0%—
3Computational Mapping of Cis Regulatory Elements in Gene Promoters1016.7%0.0%—
4Deubiquitination Mediated Stabilization of Regulatory Proteins1016.7%0.0%—
5Epigenetic and Epitranscriptomic Biomarkers for Clinical Prognosis1116.7%7.7%14
6Epitranscriptomic Regulation of Tumor Growth and Immune Evasion1116.7%7.7%15
7How Stressed Cells Rewire Their Metabolic Pathways1216.7%15.4%2
8Mechanisms of Pro-Tumor Macrophage Polarization1016.7%0.0%—
9Molecular Cascades Driving Cancer Metastasis1016.7%0.0%—
10Navigating the Narrow Therapeutic Window of Metabolic Inhibitors1016.7%0.0%—
11Overcoming the Immunosuppressive Tumor Microenvironment1216.7%15.4%3
12Reprogramming the Epigenome Through Cellular Metabolic Intermediates1016.7%0.0%—
13RNA Regulation of the Warburg Effect1016.7%0.0%—
14Targeted mRNA Decay Driven by m6A RNA Modifications1116.7%7.7%38
15The Combinatorial Logic of Post-Translational Modification Crosstalk1016.7%0.0%—
16The Limits of Single Cell Line Generalizability1016.7%0.0%—
17The Preclinical Translation Gap of Immunodeficient Models1016.7%0.0%—
18Transforming Initial Chemical Hits into Potent Therapeutic Leads1116.7%7.7%40
19Validating Novel Molecular Targets for Clinical Success1016.7%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Journal of Experimental & Clinical Cancer Research 2023 papers: a paper credits every institution named in its affiliations, once. 7 institutions share 5 credited papers.

#InstitutionPapersShare20222022 rank
1057vq6e26 240.0%0—
2Sina (China) 240.0%19
3Capital Medical University 120.0%0—
4Dalian Medical University 120.0%0—
5East China Normal University 120.0%114
6Huazhong University of Science and Technology 120.0%15
7Zhengzhou University 120.0%0—

Download all institutions as CSV

About this data

Papers. Journal of Experimental & Clinical Cancer Research 2023 lists 6 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2022 use shares, since the edition went from 13 to 6 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 5 of 6 papers (83.3%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-17 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Experimental & Clinical Cancer Research 2023”, https://lacuna.tiptreesystems.com/venue/journal-of-experimental-clinical-cancer-research/2023.

Top Authors

AuthorPapers
Pan Li1

Impactful Papers

Papers from Journal of Experimental & Clinical Cancer Research 2023 that shaped research clusters.

Influential

Papers

Title
Activation of ACLY by SEC63 deploys metabolic reprogramming to facilitate hepatocellular carcinoma metastasis upon endoplasmic reticulum stress
Correction: MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/β-catenin pathway in acute myeloid leukemia
Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer
The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer
Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth
Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment